Sunday 18 October 2026
Export AVIR’s income statement to Excel — free account
Atea Pharmaceuticals, Inc.
AVIR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
4.32
0.21
−4.64%
Follow AVIR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (58.14%) | (52.58%) | (44.34%) | (37.98%) |
+8 more TTM periods Free account |
|
| (52.99%) | (47.95%) | (40.61%) | (35.26%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(82.32%) | (73.64%) | (58.29%) | (46.45%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.90) | (1.87) | (1.62) | (1.70) | |
Free Cash Flow |
(152.07) | (147.86) | (132.03) | (134.20) | |
| Other line items | |||||
Cash ROIC |
(35.90%) | (30.19%) | (22.87%) | (20.80%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.04) | (0.04) | (0.04) | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.92 | 0.87 | 0.83 | 0.91 | |
Depreciation/Fixed assets |
(10.40) | (9.54) | (9.91) | (11.47) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.90) | (1.87) | (1.62) | (1.70) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates